Mark W Frohlich insider trades: Juno Therapeutics (JUNO) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Mark reports to the SEC
Open-market buys and sales
21 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 29, 2016 | JUNO | ↓ Sell10b5-1 | 20,000 | $35.27 | $705K | Direct | Mar 2, 2016 (2d) |
| Apr 23, 2012 | DNDN | ↓ Sell | 2,687 | $10.56 | $28K | Direct | Apr 24, 2012 (1d) |
| Jan 23, 2012 | DNDN | ↓ Sell | 3,230 | $13.24 | $43K | Direct | Jan 24, 2012 (1d) |
| Nov 14, 2011 | DNDN | ↓ Sell | 7,500 | $7.20 | $54K | Direct | Nov 16, 2011 (2d) |
| Oct 21, 2011 | DNDN | ↓ Sell | 3,230 | $10.17 | $33K | Direct | Oct 25, 2011 (4d) |
| Jul 21, 2011 | DNDN | ↓ Sell | 3,230 | $39.13 | $126K | Direct | Jul 25, 2011 (4d) |
| May 3, 2011 | DNDN | ↓ Sell | 18,000 | $40.63 | $731K | Direct | May 3, 2011 (0d) |
| Apr 21, 2011 | DNDN | ↓ Sell | 3,230 | $40.48 | $131K | Direct | Apr 25, 2011 (4d) |
| Apr 14, 2011 | DNDN | ↓ Sell | 4,282 | $40.00 | $171K | Direct | Apr 18, 2011 (4d) |
| Jan 21, 2011 | DNDN | ↓ Sell | 2,250 | $35.27 | $79K | Direct | Jan 24, 2011 (3d) |
| Jan 18, 2011 | DNDN | ↓ Sell | 2,855 | $36.78 | $105K | Direct | Jan 19, 2011 (1d) |
| Dec 3, 2010 | DNDN | ↓ Sell | 7,896 | $38.44 | $304K | Direct | Dec 7, 2010 (4d) |
| Oct 18, 2010 | DNDN | ↓ Sell | 2,855 | $37.68 | $108K | Direct | Oct 19, 2010 (1d) |
| Aug 4, 2010 | DNDN | ↓ Sell | 4,283 | $40.00 | $171K | Direct | Aug 5, 2010 (1d) |
| Apr 30, 2010 | DNDN | ↓ Sell | 43,599 | $54.44 | $2.4M | Direct | May 4, 2010 (4d) |
| Apr 6, 2010 | DNDN | ↓ Sell | 3,098 | $40.00 | $124K | Direct | Apr 7, 2010 (1d) |
| Mar 9, 2010 | DNDN | ↓ Sell | 4,876 | $36.00 | $176K | Direct | Mar 10, 2010 (1d) |
| Feb 16, 2010 | DNDN | ↓ Sell | 1,320 | $32.00 | $42K | Direct | Feb 17, 2010 (1d) |
| Sep 17, 2009 | DNDN | ↓ Sell | 4,750 | $28.00 | $133K | Direct | Sep 18, 2009 (1d) |
| Jun 2, 2009 | DNDN | ↓ Sell | 7,181 | $24.00 | $172K | Direct | Jun 8, 2009 (6d) |
| Apr 30, 2009 | DNDN | ↓ Sell | 9,482 | $22.00 | $209K | Direct | May 1, 2009 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Mark W Frohlich's insider trades
Mark W Frohlich is See Remarks at Juno Therapeutics (JUNO). Since Apr 30, 2009, Mark has reported no open-market purchases and 21 sales worth $6.0M on SEC Form 4. There have been no open-market trades in the last 12 months.
1 sale (12% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (16 filings), shares withheld for taxes (13 filings), option exercises (11 filings), shares returned to the company (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every JUNO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.